Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Michaelson

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateToni K Choueiri, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaBrian I Rini, M Dror Michaelson, Jonathan E Rosenberg, et al.
BJU International|December 5, 2013
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
The Lancet. Oncology|October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialRobert J Motzer, Thomas E Hutson, Hilary Glen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
The Oncologist|July 23, 2020
The Art of Oncology: COVID-19 EraKerry L Reynolds, Samuel J Klempner, Aparna Parikh, et al.
JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateToni K Choueiri, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaBrian I Rini, M Dror Michaelson, Jonathan E Rosenberg, et al.
BJU International|December 5, 2013
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
The Lancet. Oncology|October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialRobert J Motzer, Thomas E Hutson, Hilary Glen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
The Oncologist|July 23, 2020
The Art of Oncology: COVID-19 EraKerry L Reynolds, Samuel J Klempner, Aparna Parikh, et al.
JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Pageof 13